Fapon Biopharma and MOTE Therapeutics Unveil B-Cell Immunotherapy Strategy at BIO 2026#USA#San_Diego#Fapon_Biopharma#MOTE_Therapeutics#BIO_2026
Fapon Biopharma and MOTE Therapeutics Unveil B-Cell Immunotherapy Strategy at BIO 2026
Fapon Biopharma and MOTE Therapeutics reveal their innovative B-cell immunotherapy franchise at BIO 2026, focusing on dual-targeting strategies and gene delivery.
third-news.com
June 19, 2026 at 1:18 PM
Fapon Biopharma and MOTE Therapeutics Unveil B-Cell Immunotherapy Strategy at BIO 2026#USA#San_Diego#Fapon_Biopharma#MOTE_Therapeutics#BIO_2026
Fapon Biopharma Highlights Innovations at 2026 AACR Annual Meeting#USA#San_Diego#Fapon_Biopharma#AACR#Therapeutic_Antibodies
Fapon Biopharma Highlights Innovations at 2026 AACR Annual Meeting
Fapon Biopharma showcases its cutting-edge technology platforms and advanced pipeline at the AACR Annual Meeting 2026 in San Diego.
third-news.com
April 20, 2026 at 8:24 AM
Fapon Biopharma Highlights Innovations at 2026 AACR Annual Meeting#USA#San_Diego#Fapon_Biopharma#AACR#Therapeutic_Antibodies
Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at European Life Sciences CEO Forum#USA#Zurich#Fapon_Biopharma#TCE_Platform#CD3/TCR_VHH
Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at European Life Sciences CEO Forum
Fapon Biopharma unveiled its cutting-edge CD3/TCR VHH TCE platform at the European Life Sciences CEO Forum, aiming to revolutionize T-cell engagement technologies.
third-news.com
March 5, 2026 at 6:34 PM
Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at European Life Sciences CEO Forum#USA#Zurich#Fapon_Biopharma#TCE_Platform#CD3/TCR_VHH
Fapon Biopharma Unveils Next-Generation CD3/TCR TCE Platform at European Forum#Immunotherapy#Switzerland#Zurich#Fapon_Biopharma#CD3_TCE
Fapon Biopharma Unveils Next-Generation CD3/TCR TCE Platform at European Forum
Fapon Biopharma recently introduced its advanced CD3/TCR VHH TCE platform at the European Life Sciences CEO Forum, showcasing innovation in immunotherapy.
third-news.com
March 5, 2026 at 6:35 AM
Fapon Biopharma Unveils Next-Generation CD3/TCR TCE Platform at European Forum#Immunotherapy#Switzerland#Zurich#Fapon_Biopharma#CD3_TCE
Fapon Biopharma Unveils Next-Gen CD3/TCR VHH TCE Platform at Life Sciences Forum#United_States#Life_Sciences#Zurich#Fapon_Biopharma#T-cell_Engager
Fapon Biopharma Unveils Next-Gen CD3/TCR VHH TCE Platform at Life Sciences Forum
Fapon Biopharma announced their upcoming presentation of a pioneering T-cell engager platform at the European Life Sciences CEO Forum, revealing advancements in cancer and autoimmune disease treatment.
third-news.com
March 5, 2026 at 6:35 AM
Fapon Biopharma Unveils Next-Gen CD3/TCR VHH TCE Platform at Life Sciences Forum#United_States#Life_Sciences#Zurich#Fapon_Biopharma#T-cell_Engager
Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at CEO Forum#Switzerland#Zurich#Fapon_Biopharma#TCE_Platform#CD3/TCR_VHH
Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at CEO Forum
Discover the cutting-edge CD3/TCR VHH TCE platform that Fapon Biopharma showcased at the European Life Sciences CEO Forum, enhancing cancer treatment.
third-news.com
March 4, 2026 at 7:12 AM
Fapon Biopharma Unveils Innovative CD3/TCR VHH TCE Platform at CEO Forum#Switzerland#Zurich#Fapon_Biopharma#TCE_Platform#CD3/TCR_VHH
Fapon Biopharma Unveils Groundbreaking Anti-Cancer Fusion Protein Research#China#cancer_therapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma Unveils Groundbreaking Anti-Cancer Fusion Protein Research
Fapon Biopharma reveals the advanced anti-PD-1 X IL-10M fusion protein FP008, highlighting its potential in improving cancer immunotherapy outcomes.
third-news.com
December 23, 2025 at 5:12 AM
Fapon Biopharma Unveils Groundbreaking Anti-Cancer Fusion Protein Research#China#cancer_therapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma Initiates Phase I Clinical Trial for FP008, A Revolutionary Immunotherapy for Solid Tumors#China#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma Initiates Phase I Clinical Trial for FP008, A Revolutionary Immunotherapy for Solid Tumors
Fapon Biopharma has begun its Phase I clinical trial of FP008, a groundbreaking immunotherapy targeting solid tumors, showing promising safety profiles.
third-news.com
August 5, 2025 at 8:41 AM
Fapon Biopharma Initiates Phase I Clinical Trial for FP008, A Revolutionary Immunotherapy for Solid Tumors#China#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma to Exhibit Innovative Platforms and Pipeline at BIO 2025#United_States#Boston#Fapon_Biopharma#FP008#Immunocytokine
Fapon Biopharma to Exhibit Innovative Platforms and Pipeline at BIO 2025
Fapon Biopharma announces its participation in BIO 2025, showcasing groundbreaking therapies including Phase 1 immunocytokine FP008 and innovative technologies.
third-news.com
June 12, 2025 at 7:51 AM
Fapon Biopharma to Exhibit Innovative Platforms and Pipeline at BIO 2025#United_States#Boston#Fapon_Biopharma#FP008#Immunocytokine
Fapon Biopharma Wins FDA Approval for Innovative Immunotherapy Targeting Solid Tumors#China#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma Wins FDA Approval for Innovative Immunotherapy Targeting Solid Tumors
Fapon Biopharma has received FDA approval for FP008, a groundbreaking immunotherapy that addresses unmet needs for patients with solid tumors resistant to PD-1 therapy.
third-news.com
March 2, 2025 at 4:41 AM
Fapon Biopharma Wins FDA Approval for Innovative Immunotherapy Targeting Solid Tumors#China#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma Secures FDA Approval for Groundbreaking Solid Tumor Immunotherapy FP008#USA#FDA_Approval#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma Secures FDA Approval for Groundbreaking Solid Tumor Immunotherapy FP008
Fapon Biopharma has received FDA approval for an investigational new drug IND for FP008, a new immunotherapy targeting solid tumors resistant to PD-1 therapy.
third-news.com
March 2, 2025 at 4:30 AM
Fapon Biopharma Secures FDA Approval for Groundbreaking Solid Tumor Immunotherapy FP008#USA#FDA_Approval#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma's FDA Approval for FP008 Marks a New Era in Solid Tumor Immunotherapy#USA#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma's FDA Approval for FP008 Marks a New Era in Solid Tumor Immunotherapy
Fapon Biopharma has received FDA approval for FP008, a groundbreaking immunotherapy designed for treatment-resistant solid tumors, promising new hope for patients.
third-news.com
February 28, 2025 at 10:48 PM
Fapon Biopharma's FDA Approval for FP008 Marks a New Era in Solid Tumor Immunotherapy#USA#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma's FP008 Receives FDA Approval: A Game Changer in Solid Tumor Immunotherapy#USA#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma's FP008 Receives FDA Approval: A Game Changer in Solid Tumor Immunotherapy
Fapon Biopharma has secured FDA approval for FP008, an innovative immunotherapy addressing the vital needs of solid tumor patients resistant to existing treatments.
third-news.com
February 28, 2025 at 10:13 AM
Fapon Biopharma's FP008 Receives FDA Approval: A Game Changer in Solid Tumor Immunotherapy#USA#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Revolutionary Immunotherapy FP008 Gets FDA Nod, Offers Hope for Solid Tumor Patients#China#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Revolutionary Immunotherapy FP008 Gets FDA Nod, Offers Hope for Solid Tumor Patients
Fapon Biopharma's groundbreaking immunotherapy, FP008, has received FDA approval, marking a significant advance for solid tumor treatment strategies.
third-news.com
February 28, 2025 at 8:42 AM
Revolutionary Immunotherapy FP008 Gets FDA Nod, Offers Hope for Solid Tumor Patients#China#Immunotherapy#Dongguan#Fapon_Biopharma#FP008
Fapon Biopharma Unveils Innovative Immunotherapy Agent FP008 to Combat Refractory Cancers#United_States#San_Francisco#Cancer_Immunotherapy#Fapon_Biopharma#FP008
Fapon Biopharma Unveils Innovative Immunotherapy Agent FP008 to Combat Refractory Cancers
Fapon Biopharma announces FP008, an advanced immunotherapy targeting resistant cancers. This novel treatment could transform outcomes for patients.
third-news.com
January 2, 2025 at 9:20 AM
Fapon Biopharma Unveils Innovative Immunotherapy Agent FP008 to Combat Refractory Cancers#United_States#San_Francisco#Cancer_Immunotherapy#Fapon_Biopharma#FP008